Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity (Q48289941)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Toxoplasma gondii

0 references

0 references

1 reference

based on heuristic

inferred from title

Cristiana C. Garcia

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Oscar Bruna-Romero

7

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Ricardo Gazzinelli

9

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Alexandre Vieira Machado

object named as

Alexandre V Machado

1

0 references

author name string

Bráulia C Caetano

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Rafael P Barbosa

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Ana Paula C Salgado

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Renata H Rabelo

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Nicolas Escriou

8

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

language of work or name

0 references

publication date

26 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

28

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

18

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

3247-3256

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

Vaccination greatly reduces disease, disability, death and inequity worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Parasite vaccines: the new generation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

The role of Toll-like receptors in the host response to viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Toll or toll-free adjuvant path toward the optimal vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Innate sensors of influenza virus: clues to developing better intranasal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Activation of toll-like receptor signaling pathway for protection against influenza virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Emerging role of dendritic cells in respiratory viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium y

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Characterization ofin VivoPrimary and Secondary CD8+T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Amplification, expression, and packaging of foreign gene by influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

RNA polymerase I-mediated expression of influenza viral RNA molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Mutations in the nonconserved noncoding sequences of the influenza A virus segments affect viral vRNA formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Influenza A virus RNA polymerase has the ability to stutter at the polyadenylation site of a viral RNA template during RNA replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Selective incorporation of influenza virus RNA segments into virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic genomic segment with an internal promoter

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5' terminal sequence: induction of heterospecific B and T cell responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Toxoplasmic encephalitis in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Development of a vaccine for toxoplasmosis: current status

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Jump-starting the immune system: prime-boosting comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Toll-like receptor-mediated activation of neutrophils by influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Subversion of innate and adaptive immune responses by Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Protective immunity induced by vaccination with SAG1 gene-transfected cells against Toxoplasma gondii-infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Immunopathogenesis of toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Mucosal defences against orally acquired protozoan parasites, emphasis on Toxoplasma gondii infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Lamina propria CD4+ T lymphocytes synergize with murine intestinal epithelial cells to enhance proinflammatory response against an intracellular pathogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Toxoplasma gondii and mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Mucosal immune response in toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Mucosal immunity in Toxoplasma gondii infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.02.003

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20189485

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48289941&oldid=2194319450"